LIGHT AI ANNOUNCES CORPORATE RESTRUCTURING TO SUPPORT NEXT PHASE OF QUICKSCAN™ DEVELOPMENT

PR Newswire
Today at 10:48pm UTC

LIGHT AI ANNOUNCES CORPORATE RESTRUCTURING TO SUPPORT NEXT PHASE OF QUICKSCAN™ DEVELOPMENT

Canada NewsWire

Company implements staffing and operating cost reductions of approximately 40% to preserve capital and focus on AI-powered medical device development

VANCOUVER, BC, Nov. 18, 2026 /CNW/ -- Light AI Inc. ("Light AI" or the "Company") (Cboe Canada: ALGO) (FSE: 0HC) (OTCQB: OHCFF), a healthcare technology company developing artificial intelligence-powered software-as-a-medical-device ("SaMD") solutions, today announced the implementation of a corporate restructuring designed to reduce operating expenditures, preserve financial resources and align the Company's operations with its ongoing QuickScan™ Strep A development and remediation activities.

The restructuring follows the Company's October 2, 2026, product development update and reflects its continued focus on a disciplined, evidence-based approach to evaluating and advancing its AI-powered medical imaging technology.

Corporate Restructuring and Cash Preservation

As part of the restructuring, Light AI is implementing reductions in staffing and consulting resources, with an anticipated decrease of approximately 40% in monthly operating expenditures, subject to completion of the restructuring process and associated contractual obligations.

These measures are intended to extend the Company's available cash runway while retaining the essential technical, quality assurance, regulatory affairs, engineering and verification and validation ("V&V") capabilities necessary to support its development activities.

The Company's near-term priorities include:

  • Continuing CAPA-7 corrective and preventive action activities, including design-control and quality-system remediation;
  • Evaluating the robustness of its existing machine-learning model and supporting datasets to determine appropriate remediation or redevelopment requirements;
  • Assessing compatible, controlled medical imaging technologies for potential integration with the QuickScan platform;
  • Strengthening design controls, software verification and validation, risk management and supporting quality-system documentation; and
  • Preserving financial resources while evaluating future development, regulatory and strategic opportunities.

"Light AI is undertaking a deliberate operational restructuring to align our resources with the work required to advance our technology responsibly," said John R. Luna, Chief Executive Officer and Director of Light AI.

"Our immediate focus is on preserving the Company's financial resources, retaining the essential expertise required to execute our development and quality remediation activities, and establishing the objective evidence necessary to support future clinical and regulatory decisions. We believe these measures will provide a more focused operating structure for the Company's next phase of development."

Positioning Light AI for the Future

The restructuring represents a transition toward a leaner operating model focused on the Company's core AI and machine-learning capabilities, intellectual property and development of medical imaging applications.

Consistent with its previously announced development priorities, Light AI will continue evaluating its existing technology, including potential ML remediation or redevelopment and alternative imaging approaches, under appropriate design-control and quality-management processes.

The Company will assess subsequent clinical and regulatory activities based on the results of these efforts, available financial resources and applicable regulatory requirements.

Management believes that maintaining financial discipline, strengthening the Company's technical evidence base and focusing resources on defined development priorities will support the Company's evaluation of future opportunities for the QuickScan platform.

Light AI intends to provide further public updates as material developments warrant disclosure in accordance with applicable securities laws.

About Light AI Inc.

Light AI Inc. is a healthcare technology company focused on developing artificial intelligence-powered SaMD solutions designed to support rapid, accessible clinical assessment at the point of care. The Company's core technology, Light AI QuickScan™, is a device-agnostic software platform that applies proprietary artificial intelligence and machine learning algorithms to medical images to provide healthcare professionals with actionable clinical information within seconds. The QuickScan™ platform is designed to operate across compatible imaging and computing hardware, providing flexibility for integration into a range of healthcare devices, clinical workflows and care settings without dependence on a single proprietary hardware platform.

On Behalf of the Company

John R. Luna
Chief Executive Officer
Light AI Inc.

Telephone: (888) 804-9459
Email: jluna@light.ai
Website: www.light.ai

Forward-Looking Information

This news release contains "forward-looking statements" and "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements contained herein that are not clearly historical in nature may constitute forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as "anticipate," "believe," "expect," "estimate," "intend," "plan," "project," "target," "potential," "will," "may," "could," "should," "would," and similar expressions. These forward looking statements include the Company's expectations regarding its, anticipated operating cost reductions, preservation and extension of cash runway, implementation of restructuring activities, continued technical remediation, machine-learning assessment and development, imaging-system evaluation, future clinical and regulatory activities, potential strategic or commercial opportunities, and the Company's business strategy, development plans, and market opportunities. Forward looking statements are subject to certain risks and uncertainties inherent in the Company's business that could cause actual results to vary, including such risks with the Company's ability to successfully execute its business plans, the Company's ability to raise additional capital, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, the QuickScan™ platform does not perform as anticipated in clinical or actual patient settings, risks associated with the development, validation, and ongoing performance of artificial intelligence and machine learning algorithms, including algorithmic bias, data quality issues, and cybersecurity vulnerabilities, protection offered by the Company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company's products will not be as large as expected, and other risks detailed from time to time in the Company's documents filed under its SEDAR+ profile at www.sedarplus.ca. Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking statement speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company's management to predict all of such factors and to assess in advance the impact of each such factor on the Company's business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. The Company does not undertake any obligation to update any forward-looking information to reflect information, events, results, circumstances or otherwise after the date hereof or to reflect the occurrence of unanticipated events, except as required by law including securities laws.

SOURCE Light AI Inc.